Literature DB >> 11781379

Laminin binding to the calreticulin fragment vasostatin regulates endothelial cell function.

Lei Yao1, Sandra E Pike, Giovanna Tosato.   

Abstract

Vasostatin, the 1-180 amino acids NH(2) domain of calreticulin, inhibits endothelial cell proliferation, angiogenesis, and tumor growth, but the mechanisms underlying these effects are unclear. We show that endothelial cells express the extracellular matrix protein laminin, including chains alpha 5 and gamma 1 and that vasostatin specifically binds to laminin. When added to endothelial cell cultures, vasostatin specifically inhibits endothelial cell attachment to laminin and by this mechanism, can reduce subsequent endothelial cell growth induced by basic fibroblast growth factor. As an angiogenesis inhibitor that specifically disrupts endothelial cell attachment to components of the extracellular matrix, vasostatin has a unique potential as a cancer therapeutic.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11781379

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  14 in total

1.  Wnts induce migration and invasion of myeloma plasma cells.

Authors:  Ya-Wei Qiang; Katie Walsh; Lei Yao; Noemi Kedei; Peter M Blumberg; Jeffrey S Rubin; John Shaughnessy; Stuart Rudikoff
Journal:  Blood       Date:  2005-05-10       Impact factor: 22.113

2.  Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesis.

Authors:  Wen-Fang Cheng; Chien-Fu Hung; Chi-An Chen; Chien-Nan Lee; Yi-Ning Su; Chee-Yin Chai; David A K Boyd; Chang-Yao Hsieh; T-C Wu
Journal:  Vaccine       Date:  2004-11-24       Impact factor: 3.641

3.  Antiangiogenic and antitumor effects of Trypanosoma cruzi Calreticulin.

Authors:  Nandy C López; Carolina Valck; Galia Ramírez; Margarita Rodríguez; Carolina Ribeiro; Juana Orellana; Ismael Maldonado; Adriana Albini; Daniel Anacona; David Lemus; Lorena Aguilar; Wilhelm Schwaeble; Arturo Ferreira
Journal:  PLoS Negl Trop Dis       Date:  2010-07-06

Review 4.  Calreticulin: non-endoplasmic reticulum functions in physiology and disease.

Authors:  Leslie I Gold; Paul Eggleton; Mariya T Sweetwyne; Lauren B Van Duyn; Matthew R Greives; Sara-Megumi Naylor; Marek Michalak; Joanne E Murphy-Ullrich
Journal:  FASEB J       Date:  2009-11-25       Impact factor: 5.191

5.  Novel fusion protein derived from vasostatin 30 and vasoinhibin II-14.1 potently inhibits coronary endothelial cell proliferation.

Authors:  Gabriela Vazquez Rodriguez; Carmen Gonzalez; Antonio De Leon Rodriguez
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

6.  Protein processing by the placental protease, cathepsin P.

Authors:  M Hassanein; A Sri Bojja; L Glazewski; G Lu; R W Mason
Journal:  Mol Hum Reprod       Date:  2009-04-03       Impact factor: 4.025

Review 7.  Venom proteins of the parasitoid wasp Nasonia vitripennis: recent discovery of an untapped pharmacopee.

Authors:  Ellen L Danneels; David B Rivers; Dirk C de Graaf
Journal:  Toxins (Basel)       Date:  2010-03-30       Impact factor: 4.546

8.  An antiangiogenic neurokinin-B/thromboxane A2 regulatory axis.

Authors:  Saumen Pal; Jing Wu; Justin K Murray; Samuel H Gellman; Michele A Wozniak; Patricia J Keely; Meghan E Boyer; Timothy M Gomez; Sean M Hasso; John F Fallon; Emery H Bresnick
Journal:  J Cell Biol       Date:  2006-09-25       Impact factor: 10.539

9.  Influence of levamisole and other angiogenesis inhibitors on angiogenesis and endothelial cell morphology in vitro.

Authors:  Tina Friis; Anne-Marie Engel; Christine D Bendiksen; Line S Larsen; Gunnar Houen
Journal:  Cancers (Basel)       Date:  2013-06-24       Impact factor: 6.639

10.  Human survivin and Trypanosoma cruzi calreticulin act in synergy against a murine melanoma in vivo.

Authors:  Lorena Aguilar-Guzmán; Lorena Lobos-González; Carlos Rosas; Gerardo Vallejos; Cristián Falcón; Eduardo Sosoniuk; Francisca Coddou; Lisette Leyton; David Lemus; Andrew F G Quest; Arturo Ferreira
Journal:  PLoS One       Date:  2014-04-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.